

Blue Cross Blue Shield/Blue Care Network of Michigan Medication Authorization Request Form



This form is to be used by participating physicians to obtain coverage for **drugs covered under the medical benefit**. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

| PATIENT INFORMATION | PHYSICIAN INFORMATION |
|--|--|
| Name | Name |
| ID Number | Specialty |
| D.O.B. <input type="checkbox"/> Male <input type="checkbox"/> Female | Address |
| Diagnosis | City /State/Zip |
| Drug Name ILARIS | Phone: |
| Dose and Quantity | Fax: |
| Directions | NPI |
| Date of Service(s) | Contact Person |
| | Contact Person Phone / Ext. |

STEP 1: DISEASE STATE INFORMATION

Required Demographic Information:

Patient Weight: _____ kg
 Patient Height: _____ ft _____ inches

Will the provider be administering the medication to the FEP member within the health plan’s geographic service area?
 Yes No *If No, a prior authorization is not required through this process.*

Prior authorizations are required for FEP members that will be serviced by a provider within the health plan’s geographic service area. If you are not a provider in the geographic service area, please contact the health plan for questions regarding the FEP member’s benefit requirements.

Is this member’s FEP coverage primary or secondary coverage?
 If primary, continue with question set.
 If secondary, **an authorization is not needed through this process. Please contact the member’s primary coverage for determination of benefit and additional information.**

Site of Care:

- A. At what location will the member be receiving the requested medication?
- Physician’s office, home infusion, non-hospital affiliated ambulatory infusion center.
 - Outpatient hospital infusion center. Please provide the name of the infusion center and rationale why the patient must receive this medication in a hospital outpatient setting. _____
 - Other. Please specify. _____

Confidentiality notice: This transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of this document is strictly prohibited. If you have received this in error, please notify the sender to arrange for the return of this document.

Criteria Questions:

1. What is the patient's diagnosis?
 - Cold-Induced Auto-inflammatory Syndrome-1 (CIAS1)
 - Familial Cold Auto-inflammatory Syndrome (FCAS) a form of Cryopyrin-Associated Periodic Syndromes (CAPS)
 - Familial Mediterranean Fever (FMF)
 - Hyperimmunoglobulin D Syndrome (HIDS) / Mevalonate Kinase Deficiency (MKD)
 - Muckle-Wells Syndrome (MWS) a form of Cryopyrin-Associated Periodic Syndromes (CAPS)
 - Still's Disease, including Adult-Onset Still's Disease (AOSD)
 - a. Is the patient's condition considered to be active? Yes No
 - b. Has the patient been on Ilaris continuously for the last **6 months, excluding samples**? Yes* No
 - *If **YES**, has the patient's condition improved or stabilized while on Ilaris therapy? Yes No
 - Systemic Juvenile Idiopathic Arthritis (SJIA)
 - a. Is the patient's condition considered to be active? Yes No
 - b. Has the patient been on Ilaris therapy continuously for the last **6 months, excluding samples**? Yes* No
 - *If **YES**, has the patient's condition improved or stabilized while on Ilaris therapy? Yes No
 - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS)
 - Other diagnosis (*please specify*): _____
2. Will the patient be concurrently using a Tumor Necrosis Factor (TNF) antagonist? Yes No
3. Will the patient be concurrently using an interleukin-1 receptor antagonist? Yes No
4. Does the patient have evidence of an active infection requiring medical intervention? Yes No
5. Has the patient been on Ilaris therapy continuously for the last **6 months, excluding samples**? Yes No

Chart notes are required for the processing of all requests. Please add any other supporting medical information necessary for our review (required)

Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.

Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function

| Physician's Name | Physician Signature | Date |
|-----------------------------|---|--|
| Step 2: Checklist | <input type="checkbox"/> Form Completely Filled Out <input type="checkbox"/> Provide chart notes | <input type="checkbox"/> Attach test results |
| Step 3: Submit | By Fax: BCBSM Specialty Pharmacy Mailbox 1-877-325-5979 | By Mail: BCBSM Specialty Pharmacy Program P.O. Box 312320, Detroit, MI 48231-2320 |

Confidentiality notice: This transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of this document is strictly prohibited. If you have received this in error, please notify the sender to arrange for the return of this document.